Ranbaxy

Ranbaxy Laboratories LimitedTo become a Research based International

Pharmaceutical Company

Presented By:Aniruddha NayakRoll- 7PGDM- II

(Since 1961)

Key Drivers of Pharma Growth

Significant patent expiries

through 2011

Rationalizing Healthcare costs

- key priority for Governments

Increasing genericisation

0

5

10

15

20

25

30

35

2006 2007 2008 2009 2010 2011

France Spain Italy

Russia South Africa India

$ Bn

Value of Drugs going off patent 2006 - 11

Source : IMS

Accelerating branded generics

Key Issues

Increasing competition

Increasing focus on costs

Consolidation - Changing Landscape

The India Pharma Story

Source – Financial Times

The Indian Pharmaceutical Industry today is in the front rank of India’s science-based industries .

The Indian Pharma Industry is estimated to be worth $ 4.5 billion, growing at about 8 to 9 percent annually.

The Indian Pharmaceutical sector is highly fragmented with more than 20,000 registered units

Several Indian pharmaceutical companies have acquired companies in the US and Europe and many others .

Ranbaxy Today

India's largest

Ranked 8th amongst the global generic

pharmaceutical companies

Ground presence in 49 countries, products sold in > 125

International business ~ 80% of sales

Manufacturing locations in 11 countries

> 11,000 employees, 51 nationalities

Strong Generics & Innovative research capabilities2001 2003 2006

$ 553

$ 972

$ 1339

CAGR 19 %

Global Sales

Worldwide Presence

For the year 2008, the Company recorded Global Sales of US $ 1,682 Mn,

R&D has a pool of over 1,200 scientists engaged in research

Products sold in over 40 countries; manufacturing operations in 6 countries including India

Employs about 7000 people, 17% of non Indian origin

Expanding portfolio of international subsidiaries, joint ventures, affiliates and alliances

Ranbaxy11% GSK

1%

Cipla13%

Nicholas7%

Cadilla8%

Others60%

MISSION:-

“To become a research based international pharmaceutical company”.

VISION:-

Achieving customer satisfaction is fundamental to our business. Provide product and service of the highest quality.

Manage our operation with high concern for strategy and environment. Be a responsible corporate citizen.

India

Fastest growing Company in India (Source :ORG-IMS Mat Mar 2007)

65 new products introduced in 2006

Dedicated task forces for Specialized & Chronic therapies

21 brands in Top 300 of Industry ( 2005 :19)

First to market 10

NDDS 6

In-licensed 8

Source : ORG – IMS Audit Nov 2006, Moving Quarter Basis

GSKCipla

Ranbaxy

5.0%

4.9%

5.1%

Source : IMS - ORG

Research & Development

New R&D facility for Drug

Discovery Research (DDR)

R&D I

R&D III

R&D II R&D IV

Research & Development

Dedicated Facilities for Innovative & Generics Research

> 1400 R&D Personnel ( ~ 250 PhD’s)

8 - 10 NCE molecules in pipeline

NDDS based products ( 4 platform technologies)

R&D collaborations

Alliance / Collaboration in DDR

Out-licensing

in NDDS

Out-licensing

in DDR

Ranbaxy – GSK Collaboration

Expansion of strategic alliance established in 2003

Take leads beyond candidate selection to POC* in man

Therapeutic area focus of AI, Metabolic, Anti-inflammatory

and Oncology

> US$ 100 mn in milestone payments and double digit

royalties on commercialization of a product

Co- marketing rights in India

First candidate identified for Respiratory Inflammation

Proof of Concept

Major Acquisitions & Alliances

Terapia (Romania)

Be-Tabs (South Africa)

Allen (Italy)

Ethimed (Belgium)

Mundogen (Spain)

Zenotech (India)

Krebs (India)

Jupiter Biosciences*(Ind.)

Cardinal Drugs (India)

Auto-injector Tech.(USA)

* Subject to due diligence

Niche Alliances

Increasing focus on chronic / lifestyle diseases segment

High entry barriers - technology & resource intensive

Fermentation

based products

Bio-similars &

Oncologics

Peptides

KrebsZenotech Jupiter*

* Subject to due diligence

BRAND RANBAXY

OPINION OF DOCTORS TOWARDS RANBAXY PRODUCTS QUALITY

Ranbaxy Brands

 •  Analgesics  •  Anti-Peptic Ulcerants  

 •  Cardiovasculars  •  Cephalosporins  

 •  CNS  •  Combination Therapy  

 •  Cough Preparations & Anti-Histamines  •  Dermatologicals  

 •  Diagnostic Instruments  •  Nutritionals  

 •  Oral Anti-Diabetics  •  Orthopaedic Segment  

 •  Other Anti-Infectives  •  Others  

 •  Quinolones  •  Reagents-Biochemistry  

 •  Reagents-Cardiac Markers  •  Reagents-HIV/Hepatitis  

 •  Reagents-Serology  •  Reagents-Torch Range  

 •  Semi-Synthetic Penicillins  

Repositioning Ranbaxy

underwent a sea change during the period 1985-1995

diversified into different products, markets and in general over the ‘value curve’

tried to create differentiation through Marketing and Process Technology, resulted in improved product/brand profitability, and an increase in brand life cycle

one of the top brands from the Ranbaxy stable that made a successful transition from prescription to OTC markets in India.

Ranbaxy's Revital successfully shifted from prescription to OTC and became a market leader. 

“Jiyo Jee Bhar Ke”

Yuvraj bats for Ranbaxy’s healthcare brand

‘Revital’ising the brand

In Summary A strong performance on all parameters

Buoyant performance across key geographies

Continuing focus on cost optimization

Robust product flow

Growth through organic & inorganic

Discovery pipeline progressing well

Global Generic rank – 8th

Thank You …